CS/HB 1465 requires the Agency for Health Care Administration to seek federal approval, within 30 days after the bill becomes law, to cover continuous glucose monitors and related supplies as a durable medical equipment benefit under Florida Medicaid. The bill directs the agency to pursue either a Medicaid waiver or a state plan amendment, as needed, and to reimburse licensed durable medical equipment providers for these items when claims are submitted through an active Medicare HCPCS code. It also bars the agency from requiring a National Drug Code number for those claims.
The bill further clarifies that this new durable medical equipment coverage does not prevent the agency from also covering continuous glucose monitors through the Medicaid pharmacy benefit. Implementation would begin once any necessary federal approval is obtained, and the act takes effect immediately upon becoming law. In practical terms, the measure is aimed at expanding and standardizing Medicaid access to continuous glucose monitors for eligible recipients, including associated supplies.
Impact
The bill would amend how Florida Medicaid can cover and reimburse continuous glucose monitors, shifting them into a durable medical equipment framework if federal approval is granted. It would require AHCA to take affirmative steps to secure federal authorization and would affect Medicaid recipients, durable medical equipment providers, and claims processing rules by specifying HCPCS-based billing and prohibiting an NDC requirement. The bill does not itself guarantee immediate coverage absent federal approval, but it creates a mandatory state process to pursue that coverage and implement it once approved.
Sentiment
The available voting history shows strong bipartisan or at least broad committee support, with unanimous 15-0 votes in both the House Health Care Facilities & Systems Subcommittee and the House Health Care Budget Subcommittee. No committee transcript objections are provided, and the bill’s framing suggests a generally favorable view of expanding access to diabetes management technology for Medicaid enrollees. Overall, the sentiment appears positive and noncontroversial in committee.
Contention
No major points of contention are reflected in the provided materials. The only potentially sensitive issues are administrative and fiscal: whether AHCA must obtain federal approval through a waiver or state plan amendment, how the benefit should be categorized for Medicaid purposes, and how providers should bill for reimbursement. The bill also preserves agency flexibility to cover continuous glucose monitors as a pharmacy benefit, which may reduce conflict over the exact coverage pathway.